ARCHIVES

Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems

This article is from The Cancer Letter archive.

Vol. 21 No. 43 | November 10, 1995

Download PDF Visit The Full Archive

Related Articles

Gynecologic Oncology Group To Conduct Phase III Trial of Xyotax For Ovarian Cancer

April 30, 2004

Group Chairs Respond to Center Directors’ White Paper

April 1, 2011

Commission Urges Bypass Funding for Breast Cancer

November 5, 1993

FDA’s Oncologic Drugs Advisory Committee recommended approval of three drugs for cancer, voted down one.

September 16, 2005

Minorities Increasingly Involved In Research, Training Programs

December 5, 1986

Special Report on the American Legacy Foundation: As Legacy seeks new funding, critics fear symbiosis with Big Tobacco. Legacy, NCI, C-Change relationship could open door to industry influence, lawyer says.

October 29, 2004